1,25(OH)2D3 inhibits the progression of hepatocellular carcinoma via downregulating HDAC2 and upregulating P21(WAFI/CIP1)

Huang,Jian; Yang,Guozhen; Huang,Yunzhu; Kong,Weiying; Zhang,Shu

doi:10.3892/mmr.2015.4676

1,25(OH)2D3 inhibits the progression of hepatocellular carcinoma via downregulating HDAC2 and upregulating P21(WAFI/CIP1)

Authors:
- Jian Huang
- Guozhen Yang
- Yunzhu Huang
- Weiying Kong
- Shu Zhang
View Affiliations

Affiliations: Biochemistry Department, Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou 550004, P.R. China, Medical Laboratory, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China, Biochemistry Department, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China
Published online on: December 11, 2015 https://doi.org/10.3892/mmr.2015.4676
Pages: 1373-1380

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vitamin D, termed 1,25(OH)2D3 in it's active form, activity is associated with a reduced risk of hepatocellular carcinoma (HCC) and is an important immune regulator. However, the detail molecular mechanisms underlying the effects of 1,25(OH)2D3 on the progression of HCC are widely unknown. Histone deacetwylase 2 (HDAC2) is usually expressed at high levels in tumors, and its downregulation leads to high expression levels of cell cycle components, including p21(WAF1/Cip1), a well‑characterized modulator, which is critical in cell senescence and apoptosis. The present study investigated whether vitamin D inhibits HCC via the regulation of HDAC2 and p21(WAF1/Cip1). Firstly, the toxic concentrations of 1,25(OH)2D3 were determined, according to trypan blue and [3H]thymidine incorporation assays. Secondly, HCC cells lines were treated with different concentrations of 1,25(OH)2D3. The expression of HDAC2 was either silenced via short hairpin (sh)RNA or induced by transfection of plasmids expressing the HDAC2 gene in certain HCC cells. Finally the mRNA and protein levels of HDAC2 and p21(WAF1/Cip1) were measured using reverse transcription‑quantitative polymerase chain reaction and western blot analyses. The results revealed that 1,25(OH)2D3 treatment reduced the expression of HDAC2 and increased the expression of p21(WAF1/Cip1), in a dose‑dependent manner, resulting in the reduction of HCC growth. Elevated levels of HDAC2 reduced the expression of p21(WAF1/Cip1), resulting in an increase in HCC growth. HDAC2 shRNA increased the expression of p21(WAF1/Cip1), resulting in reduction in HCC growth. Thus, 1,25(OH)2D3 exerted antitumorigenic effects through decreasing the expression levels of HDAC2 and increasing the expression of p21(WAF1/Cip1), which inhibited the development of HCC and may indicate the possible underlying mechanism. These results suggest that vitamin D3 may be developed as a potential drug for effective therapy in the treatment of HCC.

View Figures

View References

1	Tang B, Zhang Y, Liang R, Gao Z, Sun D and Wang L: RNAi-mediated EZH2 depletion decreases MDR1 expression and sensitizes multidrug-resistant hepatocellular carcinoma cells to chemotherapy. Oncol Rep. 29:1037–1042. 2013.PubMed/NCBI
2	Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Imajo K, Kato S, Suzuki K, Kobayashi N, Kubota K, Maeda S, et al: Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol. 18:1933–1939. 2012. View Article : Google Scholar : PubMed/NCBI
3	Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Brú C, Rodés J and Bruix J: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 29:62–67. 1999. View Article : Google Scholar
4	Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA and Giulini SM: Early and late recurrence after liver resection for hepatocellular carcinoma: Prognostic and therapeutic implications. Ann Surg. 243:229–235. 2006. View Article : Google Scholar : PubMed/NCBI
5	Lu L, Sun HC, Zhang W, Chai ZT, Zhu XD, Kong LQ, Wang WQ, Zhang KZ, Zhang YY, Zhang QB, et al: Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. PLoS One. 8:e650232013. View Article : Google Scholar : PubMed/NCBI
6	Deeb KK, Trump DL and Johnson CS: Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nat Rev Cancer. 7:684–700. 2007. View Article : Google Scholar : PubMed/NCBI
7	Gocek E and Studzinski GP: Vitamin D and differentiation in cancer. Crit Rev Clin Lab Sci. 46:190–209. 2009. View Article : Google Scholar : PubMed/NCBI
8	Bhalla AK, Amento EP, Clemens TL, Holick MF and Krane SM: Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: Presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab. 57:1308–1310. 1983. View Article : Google Scholar : PubMed/NCBI
9	Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park H, Lee JY and Nam SW: HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J Cell Biochem. 113:2167–2177. 2012. View Article : Google Scholar : PubMed/NCBI
10	Kim HS, Chang YG, Bae HJ, Eun JW, Shen Q, Park SJ, Shin WC, Lee EK, Park S, Ahn YM, et al: Oncogenic potential of CK2α and its regulatory role in EGF-induced HDAC2 expression in human liver cancer. FEBS J. 281:851–861. 2014. View Article : Google Scholar : PubMed/NCBI
11	Shimizu T, LoRusso PM, Papadopoulos KP, Patnaik A, Beeram M, Smith LS, Rasco DW, Mays TA, Chambers G, Ma A, et al: Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR and HER2 in patients with advanced solid tumors. Clin Cancer Res. 20:5032–5040. 2014. View Article : Google Scholar : PubMed/NCBI
12	Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, et al: Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res. 1:62–71. 2009.PubMed/NCBI
13	Noh JH, Bae HJ, Eun JW, Shen Q, Park SJ, Kim HS, Nam B, Shin WC, Lee EK, Lee K, et al: HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT. Cancer Res. 74:1728–1738. 2014. View Article : Google Scholar : PubMed/NCBI
14	Noh JH, Jung KH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park WS, Lee JY and Nam SW: Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS One. 6:e281032011. View Article : Google Scholar : PubMed/NCBI
15	Parra E, Gutiérrez L and Ferreira J: Increased expression of p21Waf1/Cip1 and JNK with costimulation of prostate cancer cell activation by an siRNA Egr-1 inhibitor. Oncol Rep. 30:911–916. 2013.PubMed/NCBI
16	Sachidanandam R: RNAi: design and analysis. Current Protocols in Bioinformatics. 13:10–11. 2004.
17	Abe J, Nakano T, Nishii Y, Matsumoto T, Ogata E and Ikeda K: A Novel Vitamin-D3 Analog, 22-Oxa-1,25-Dihydroxyvitamin-D3, Inhibits the Growth of Human Breast-Cancer Invitro and Invivo without Causing Hypercalcemia. Endocrinology. 129:832–837. 1991. View Article : Google Scholar : PubMed/NCBI
18	Giovannucci E: Vitamin D and cancer incidence in the harvard cohorts. Ann Epidemiol. 19:84–88. 2009. View Article : Google Scholar
19	Pourgholami MH, Akhter J, Lu Y and Morris DL: In vitro and in vivo inhibition of liver cancer cells by 1,25-dihydroxyvitamin D3. Cancer Lett. 151:97–102. 2000. View Article : Google Scholar : PubMed/NCBI
20	Methot JL, Hoffman DM, Witter DJ, Stanton MG, Harrington P, Hamblett C, Siliphaivanh P, Wilson K, Hubbs J, Heidebrecht R, et al: Delayed and prolonged histone hyperacetylation with a selective HDAC1/HDAC2 inhibitor. ACS Med Chem Lett. 5:340–345. 2014. View Article : Google Scholar : PubMed/NCBI
21	Ma P and Schultz RM: Histone deacetylase 2 (HDAC2) regulates chromosome segregation and kinetochore function via H4K16 deacetylation during oocyte maturation in mouse. PLoS Genet. 9:e10033772013. View Article : Google Scholar : PubMed/NCBI
22	Di Padova M, Bruno T, De Nicola F, Iezzi S, D'Angelo C, Gallo R, Nicosia D, Corbi N, Biroccio A, Floridi A, et al: Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoter. J Biol Chem. 278:36496–36504. 2003. View Article : Google Scholar : PubMed/NCBI
23	Wang W, Xu L, Kong J, Fan H and Yang P: Quantitative research of histone H3 acetylation levels of human hepatocellular carcinoma cells. Bioanalysis. 5:327–339. 2013. View Article : Google Scholar : PubMed/NCBI
24	Küçükazman M, Ata N, Dal KA, Yeniova AÖ, Kefeli A, Basyigit S, Aktas B, Akin KO, Ağladıoğlu K, Üre ÖS, et al: The association of vitamin D deficiency with non-alcoholic fatty liver disease. Clinics (Sao Paulo). 69:542–546. 2014. View Article : Google Scholar
25	Mandorfer M, Payer BA, Schwabl P, Steiner S, Ferlitsch A, Aichelburg MC, Stättermayer AF, Ferenci P, Obermayer-Pietsch B, Grabmeier-Pfistershammer K, et al: Revisiting liver disease progression in HIV/HCV-coinfected patients: The influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. Liver Int. 35:876–885. 2014. View Article : Google Scholar : PubMed/NCBI